Literature DB >> 25230248

Affinity-based drug delivery systems for tissue repair and regeneration.

Katarina Vulic1, Molly S Shoichet.   

Abstract

Affinity-based release systems use transient interactions to sustain and control the release of a therapeutic from a polymeric matrix. The most common affinity-based systems use heparin-based scaffolds to sustain the release of heparin-binding proteins, such as fibroblast growth factor-2 (FGF2) and vascular endothelial growth factor (VEGF). However, novel affinity-based systems based on, for example, protein-protein or DNA-protein interactions, are emerging to control the release of an expanding repertoire of therapeutics. Mathematical models of affinity-based systems have provided a thorough understanding of which parameters affect release rate from these systems, and how these release rates can be tuned. In this review, recent affinity-based release systems will be described, including an overview of the various types of affinity interactions used to modulate release, the mechanisms by which release from these systems is tuned, and the time scales of sustained release. This advanced drug delivery paradigm provides tunable and predictable release rates and has expanded the scope of deliverable therapeutics for tissue repair and regeneration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25230248     DOI: 10.1021/bm501084u

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  25 in total

1.  Heparin-dopamine functionalized graphene foam for sustained release of bone morphogenetic protein-2.

Authors:  Qingqing Yao; Yangxi Liu; Hongli Sun
Journal:  J Tissue Eng Regen Med       Date:  2018-05-18       Impact factor: 3.963

2.  BBP-Functionalized Biomimetic Nanofibrous Scaffold Can Capture BMP2 and Promote Osteogenic Differentiation.

Authors:  Qingqing Yao; Eric S Sandhurst; Yangxi Liu; Hongli Sun
Journal:  J Mater Chem B       Date:  2017-05-30       Impact factor: 6.331

Review 3.  Programmable hydrogels.

Authors:  Yong Wang
Journal:  Biomaterials       Date:  2018-03-05       Impact factor: 12.479

4.  Cyclodextrin polymers as nanocarriers for sorafenib.

Authors:  Valentina Giglio; Maurizio Viale; Vittorio Bertone; Irena Maric; Rita Vaccarone; Graziella Vecchio
Journal:  Invest New Drugs       Date:  2017-11-08       Impact factor: 3.850

Review 5.  Controlled drug release for tissue engineering.

Authors:  Kunal J Rambhia; Peter X Ma
Journal:  J Control Release       Date:  2015-08-29       Impact factor: 9.776

Review 6.  Biomaterial strategies for limiting the impact of secondary events following spinal cord injury.

Authors:  Trevor R Ham; Nic D Leipzig
Journal:  Biomed Mater       Date:  2018-02-08       Impact factor: 3.715

7.  Affinity-controlled protein encapsulation into sub-30 nm telodendrimer nanocarriers by multivalent and synergistic interactions.

Authors:  Xu Wang; Changying Shi; Li Zhang; Alexa Bodman; Dandan Guo; Lili Wang; Walter A Hall; Stephan Wilkens; Juntao Luo
Journal:  Biomaterials       Date:  2016-06-03       Impact factor: 12.479

Review 8.  Micro/nanofabricated platforms for oral drug delivery.

Authors:  Cade B Fox; Jean Kim; Long V Le; Cameron L Nemeth; Hariharasudhan D Chirra; Tejal A Desai
Journal:  J Control Release       Date:  2015-08-02       Impact factor: 9.776

Review 9.  Using biomaterials to modulate chemotactic signaling for central nervous system repair.

Authors:  Kassondra Hickey; Sarah E Stabenfeldt
Journal:  Biomed Mater       Date:  2018-04-27       Impact factor: 3.715

10.  Tunable Controlled Release of Bioactive SDF-1α via Protein Specific Interactions within Fibrin/Nanoparticle Composites.

Authors:  D Dutta; C Fauer; H L Mulleneux; S E Stabenfeldt
Journal:  J Mater Chem B       Date:  2015-08-11       Impact factor: 6.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.